External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ESMO IO 2021

-
Coming soon
09:00 AM
Duration 10mins Room A
Dynamic circulating tumour DNA response to neoadjuvant atezolizumab▼ and surgery and association with outcomes in patients with NSCLC
Mark G. Kris, Jessica M. Grindheim, Jamie E. Chaft, Jay M. Lee, Bruce E. Johnson, Valerie W. Rusch, Paul A. Bunn, Jr, Harvey Pass, Elaine Shum, Jennifer Carlisle, Michael Weyant, Alan Nicholas, Ann Johnson, David Shames, Ignacio I. Wistuba, David P. Carbone, Katja Schulze, David J. Kwiatkowski

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
09:10 AM
Duration 10mins Room A
IMpower010: biomarkers of disease-free survival (DFS) in a Phase 3 study of atezolizumab▼ (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC
Zhou C, Das Thakur M, Srivastava MK, Zou W, Xu H, Ballinger M, Felip E, Wakelee H, Altorki N, Reck M, Liersch R, Kryzhanivska A, Harada M, Tanaka H, Hamm J, McCune S, McNally V, Bennett E, Gitlitz B, Novello S

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
09:00 AM
Duration 10mins Virtual
Updated Analysis and Patient-Reported Outcomes of CITYSCAPE: A Randomised, Double-Blind, Phase II Study of the anti-TIGIT Antibody Tiragolumab (Tira) + Atezolizumab▼ (Atezo) Versus Placebo + Atezo As First-Line Treatment For PD-L1-Selected NSCLC
Cho BC, Rodriguez-Abreu D, Hussein M, Cobo M, Patel A, Secen N, Gerstner G, Kim DW, Lee YG, Su WC, Huang E, Patil N, Huang M, Zhang Z, Wen X, Mendus D, Hoang T, Meng R, Johnson M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar